Abstract

Investigators in the Surgery Branch of the National Cancer Institute are the general surgeons and general surgical consultants to the entire National Institutes of Health. In this role we see patients in primarily two capacities. Patients are seen in consultation for all general surgical and specialty problems except for the specialties of cardiac, urologic, neurosurgery and orthopedic surgery. The Surgery Branch answers all emergency, as well as elective surgical consultations and provides 24 hour coverage for surgical emergencies that may arise in the Clinical Center Hospital. Increasing surgery in AIDS patients is being performed. The Surgery Branch also collaborates in the procurement of tissue for studies required by other investigative units. The degree of involvement of the Surgery Branch in the planning and execution of these studies is variable. The Surgery Branch often plays an instrumental role in the design of these studies while in other collaborations, the Surgical Service merely provides tissue. Approximately 40% of the clinical surgical effort of the Surgery Branch is devoted to these consultative and collaborative studies.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Intramural Research (Z01)
Project #
1Z01SC003800-37
Application #
7594751
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
37
Fiscal Year
2007
Total Cost
$875,721
Indirect Cost

  Institution

Name
National Cancer Institute Division of Clinical Sciences
Department
Type
DUNS #
City
State
Country
United States
Zip Code

  Publications

Wargo, Jennifer A; Robbins, Paul F; Li, Yong et al. (2009) Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression. Cancer Immunol Immunother 58:383-94
Heemskerk, Bianca; Liu, Ke; Dudley, Mark E et al. (2008) Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum Gene Ther 19:496-510
Breunis, Willemijn B; Tarazona-Santos, Eduardo; Chen, Renee et al. (2008) Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 31:586-90
Palmer, Douglas C; Chan, Chi-Chao; Gattinoni, Luca et al. (2008) Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 105:8061-6
Powell Jr, Daniel J; Attia, Peter; Ghetie, Victor et al. (2008) Partial reduction of human FOXP3+ CD4 T cells in vivo after CD25-directed recombinant immunotoxin administration. J Immunother 31:189-98
Klapper, Jacob A; Downey, Stephanie G; Smith, Franz O et al. (2008) High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer 113:293-301
Yang, S; Cohen, C J; Peng, P D et al. (2008) Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther 15:1411-23
Rosenberg, Steven A (2008) Why perform sentinel-lymph-node biopsy in patients with melanoma? Nat Clin Pract Oncol 5:1
Hinrichs, Christian S; Spolski, Rosanne; Paulos, Chrystal M et al. (2008) IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111:5326-33
Cortes, Lizette M; Mattapallil, Mary J; Silver, Phyllis B et al. (2008) Repertoire analysis and new pathogenic epitopes of IRBP in C57BL/6 (H-2b) and B10.RIII (H-2r) mice. Invest Ophthalmol Vis Sci 49:1946-56

Showing the most recent 10 out of 60 publications